Download Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022 Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/2845709/
Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022
Description:
Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022
Summary
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from
nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between
neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain.
Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying
etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia
and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications
include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of
multiple pain medications only 50% of patients respond to any given drug and there are numerous the side
effects associated particularly with systemically administered drugs, that reduce their tolerability. New
treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will
remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an
improved safety profile.
Qutenza (capsaicin 8% patch) was developed by NeurogesX, and is the first and only prescription-strength
capsaicin treatment. It was approved in Europe (where is it marketed under license to Astellas Pharma) in
March 2009 for the treatment of peripheral NP in non-diabetic adults, both as a monotherapy and in
combination with other products. In the US, Qutenza was approved by the FDA in November 2009 for the
treatment of PHN. NeurogesX retained the full commercial rights to Qutenza in the US and worldwide
(outside Europe).
Scope
- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Qutenza including product description, safety and efficacy profiles as well as a
SWOT analysis.
- Sales forecast for Qutenza for the top six countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales
potential
- Make more informed business decisions from insightful and in-depth analysis of Qutenza performance
- Obtain sales forecast for Qutenza from 2012-2022 in the top six countries (the US, France, Germany, Italy,
Spain and the UK).
Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms
3.1.1 Painful Diabetic Neuropathy
3.1.2 Postherpetic Neuralgia
3.1.3 Trigeminal Neuralgia
3.2 Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Overview and Guidelines
5 Competitive Assessment
5.1 Overview
6 Qutenza
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Diagnosed PDN, PHN, and TN Patients
7.4.2 Percent Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in This Study
7.6 About the Authors
7.6.1 Author
7.6.2 Global Head of Healthcare
7.7 About Us
7.8 Disclaimer
1.1 List of Tables
Table 1: Classification of NP Syndromes Based on the Site of Somatosensory Damage
Table 2: Signs and Symptoms of NP
Table 3: Screening Tools for NP
Table 4: NP-Related Signs and Symptoms
Table 5: Treatment Guidelines for NP
Table 6: Recommended Drug Therapies for NP Conditions by Line of Therapy
Table 7: Most Prescribed Drugs for NP by Indication and Line of Therapy in the Global Markets, 2012
Table 8: NNT and NNH for Classes of Oral Drugs used in NP Treatment, 2013
Table 9: Select Products Used for NP Treatment, 2013
Table 10: Product Profile - Qutenza
Table 11: Qutenza SWOT Analysis, 2013
Table 12: Global Sales Forecasts ($m) for Qutenza, 2012-2022
1.2 List of Figures
Figure 1: Nociceptive Versus Neuropathic Pain
Figure 2: Etiology and Pathophysiology of NP
Figure 3: Pain Pathway - Somatosensory System
Figure 4: Pathophysiological Mechanisms of NP at Different Levels of the Nervous System
Figure 5: Pathophysiological Targets of NP Drugs
Figure 6: NeuSPIG Diagnostic Certainty Algorithm for NP
Figure 7: General Treatment Algorithm for NP
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2845709/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Qutenza (Neuropathic Pain) - Forecast and Market Analysis to 2022
Web Address:
http://www.researchandmarkets.com/reports/2845709/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:
USD 3495
Electronic (PDF) Site License:
USD 6990
Electronic (PDF) Enterprisewide:
USD 10485
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World